title: Clinical usefulness of serum and immunohistochemical markers in patients with stage Ia and Ic ovarian cancer.
abstract: We compared the preoperative serum tumor marker values and diameters of ovarian tumors between 14 stage Ia ovarian cancer patients with a good prognosis and 14 stage Ic patients with a poor prognosis. The aim was to examine the usability of tumor markers and diameter of ovarian tumors for prognostic diagnosis of clinically advanced phases. In occult neoplastic cells (ONCs), a tumor marker indicative of recurrence and metastasis, the cytokeratin-positive cells in lymph node biopsies, were also compared. In a preoperative comparison of serum tumor markers, CA125 levels in stage Ia and Ic patients were 47.1+/-15.9 (median, 31.9 U/ml) and 370.6+/-146.2 U/ml (median, 135.6 U/ml), respectively (p=0.0457), and CA19-9 levels were 25.5+/-5.5 (median, 20.4 U/ml) and 564.5+/-192.4 U/ml (median, 248.0 U/ml), respectively (p=0.0131). In a comparison of tumor diameters during surgery, diameters of stage Ia and Ic patients were 117.3+/-11.4 (median, 100.0 mm) and 182.0+/-29.2 mm (median, 145.0 mm), respectively (p=0.0457). ONCs were not detected in any stage Ia patients, but detected in 3 (30%) stage Ic patients. In conclusion, clinical progression was evaluated using CA125 and CA19-9 serum markers and tumor diameters in stage Ia and Ic patients, and demonstrated significant differences between stage. ONCs were only detected in the lymph nodes of stage Ic patients.
authors.affiliation: Department of Obstetrics and Gynecology, Tokai University School of Medicine, Shimokasuya 143, Isehara, Kanagawa 259-1143, Japan. mura-to@is.icc.u-tokai.ac.jp
authors.forename: Toshinari
authors.initials: T
authors.lastname: Muramatsu
authors.forename: Masaya
authors.initials: M
authors.lastname: Mukai
authors.forename: Shinkichi
authors.initials: S
authors.lastname: Sato
authors.forename: Takayuki
authors.initials: T
authors.lastname: Tajima
authors.forename: Eri
authors.initials: E
authors.lastname: Nagase
authors.forename: Masae
authors.initials: M
authors.lastname: Ikeda
authors.forename: Ken-Ichi
authors.initials: K
authors.lastname: Goya
authors.forename: Masako
authors.initials: M
authors.lastname: Shida
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hirasawa
authors.forename: Masaru
authors.initials: M
authors.lastname: Murakami
authors.forename: Takao
authors.initials: T
authors.lastname: Shinozuka
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism; D001706:Biopsy; D018394:CA-125 Antigen / Q000096:biosynthesis; D018395:CA-19-9 Antigen / Q000096:biosynthesis; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007633:Keratins / Q000378:metabolism; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000473:pathology*; D011379:Prognosis; D013997:Time Factors
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; D007633:Keratins